[Federal Register Volume 87, Number 37 (Thursday, February 24, 2022)]
[Notices]
[Page 10390]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-03900]



[[Page 10390]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-955]


Bulk Manufacturer of Controlled Substances Application: 
Scottsdale Research Institute

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Scottsdale Research Institute, has applied to be registered as 
a bulk manufacturer of basic class(es) of controlled substance(s). 
Refer to Supplemental Information listed below for further drug 
information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before April 25, 2022. 
Such persons may also file a written request for a hearing on the 
application on or before April 25, 2022.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on January 10, 2022, Scottsdale Research Institute, 5436 
East Tapekim Road, Cave Creek, Arizona 85331, applied to be registered 
as a bulk manufacturer of the following basic class(es) of controlled 
substance(s):

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Psilocybin..............................    7437  I
Psilocyn................................    7438  I
------------------------------------------------------------------------

    The company plans to bulk manufacture the listed controlled 
substances for clinical trials. No other activities for these drug 
codes are authorized for this registration.

Matthew J. Strait,
Deputy Assistant Administrator.
[FR Doc. 2022-03900 Filed 2-23-22; 8:45 am]
BILLING CODE P